Marshall Wace LLP Acquires Shares of 89,314 Capricor Therapeutics Inc (NASDAQ:CAPR)

Marshall Wace LLP acquired a new stake in shares of Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 89,314 shares of the biotechnology company's stock, valued at approximately $426,000. Marshall Wace LLP owned approximately 0.28% of Capricor Therapeutics at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of CAPR. BNP Paribas Financial Markets purchased a new stake in Capricor Therapeutics during the 1st quarter valued at about $40,000. Main Street Financial Solutions LLC boosted its holdings in Capricor Therapeutics by 37.5% in the 2nd quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company's stock valued at $131,000 after purchasing an additional 7,500 shares during the last quarter. Rhumbline Advisers acquired a new position in Capricor Therapeutics in the 2nd quarter valued at about $147,000. Bank of New York Mellon Corp boosted its holdings in Capricor Therapeutics by 12.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company's stock valued at $381,000 after purchasing an additional 9,040 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its holdings in Capricor Therapeutics by 158.7% in the 2nd quarter. Renaissance Technologies LLC now owns 137,500 shares of the biotechnology company's stock valued at $656,000 after purchasing an additional 84,350 shares during the last quarter. Hedge funds and other institutional investors own 21.68% of the company's stock.

Analyst Ratings Changes

Several equities analysts have weighed in on CAPR shares. Cantor Fitzgerald reiterated an "overweight" rating and issued a $8.00 target price on shares of Capricor Therapeutics in a report on Friday, September 20th. Oppenheimer reiterated an "outperform" rating and issued a $15.00 target price on shares of Capricor Therapeutics in a report on Monday, September 23rd. HC Wainwright reiterated a "buy" rating and issued a $40.00 target price on shares of Capricor Therapeutics in a report on Wednesday. Finally, Maxim Group boosted their target price on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the company a "buy" rating in a report on Wednesday, September 25th. One research analyst has rated the stock with a sell rating and five have given a buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $22.60.

Insiders Place Their Bets

In other Capricor Therapeutics news, major shareholder Shinyaku Co Ltd Nippon bought 2,798,507 shares of Capricor Therapeutics stock in a transaction on Friday, September 20th. The shares were bought at an average cost of $5.36 per share, for a total transaction of $14,999,997.52. Following the acquisition, the insider now directly owns 7,090,351 shares in the company, valued at $38,004,281.36. This represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 12.00% of the stock is owned by company insiders.

Capricor Therapeutics Price Performance

Shares of CAPR stock traded up $0.63 during trading hours on Friday, hitting $17.77. The company had a trading volume of 4,571,023 shares, compared to its average volume of 1,081,583. The company's fifty day moving average is $7.44 and its 200 day moving average is $6.07. Capricor Therapeutics Inc has a fifty-two week low of $2.68 and a fifty-two week high of $21.98. The stock has a market capitalization of $578.24 million, a PE ratio of -19.11 and a beta of 4.01.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last issued its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.03). Capricor Therapeutics had a negative return on equity of 220.27% and a negative net margin of 102.93%. The company had revenue of $3.97 million during the quarter, compared to analyst estimates of $4.51 million. Equities analysts forecast that Capricor Therapeutics Inc will post -1.13 earnings per share for the current year.

Capricor Therapeutics Profile

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.